Flow synthesis and biological studies of an analgesic adamantane derivative that inhibits P2X7-evoked glutamate release

ACS Medicinal Chemistry Letters

Volumn 4, Issue 8, 2013, Pages 704-709

  Battilocchio, Claudio ^a   Guetzoyan, Lucie ^a   Cervetto, Chiara ^b   Di Cesare Mannelli, Lorenzo ^c   Frattaroli, Daniela ^b   Baxendale, Ian R ^d   Maura, Guido ^b   Rossi, Antonietta ^e   Sautebin, Lidia ^e   Biava, Mariangela ^f   Ghelardini, Carla ^c   Marcoli, Manuela ^b   Ley, Steven V ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d DURHAM UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

2 aminoadamantane 2 carboxylic acid; Adamantane derivatives; Analgesic agents; Flow chemistry; Purinergic receptors

Indexed keywords

2 AMINOADAMANTANE 1 CARBOXYLIC ACID; ADAMANTANE DERIVATIVE; ANALGESIC AGENT; CANNABINOID RECEPTOR; CARBOXYLIC ACID; GLUTAMIC ACID; OPIATE; PURINERGIC P2X7 RECEPTOR; RIMONABANT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; DRUG SCREENING; HYPERALGESIA; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; SYNAPTOSOME;

RATTUS;

EID: 84881459925     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400079h     Document Type: Article

References (48)

1. 7 receptors: properties and relevance to CNS function Glia 2006, 54, 738-746
2. 7 receptors in the nervous system Prog. Neurobiol. 2006, 78, 327-346
3. Burnstock, G. Physiology and pathophysiology of purinergic neurotransmission Physiol. Rev. 2007, 87, 659-797
4. 7 presynaptic receptors in adult rat cerebrocortical nerve terminals: a role in ATP-induced glutamate release J. Neurochem. 2008, 105, 2330-2342
5. 7 regenerative-loop potentiation of glutamate synaptic transmission by microglia and astrocytes J. Theor. Biol. 2009, 261, 1-16
6. 7 antagonists in the rat Br. J. Pharmacol. 2011, 162, 405-414
7. 7receptor: differences in modulation and selectivity J. Neurochem. 2010, 113, 796-806
8. North, R. A. Molecular physiology of P2X receptors Physiol. Rev. 2002, 82, 1013-1067
9. 7 receptor subtypes Br. J. Pharmacol. 2002, 135, 1616-1626
10. 7 receptors in rat brain: presence in synaptic terminals and granule cells Neurochem. Res. 2003, 28, 1597-1605
11. 7 receptors activation in cerebellar granule neurons Neurochem. Int. 2008, 52, 1148-1159
12. 7 receptor as a route for non-exocytotic glutamate release: dependence on the carboxyl tail J. Neurochem. 2013, 124, 821-31
13. 7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia Neurobiol. Dis. 2012, 45, 954-961
14. Di Virgilio, F. The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death Immunol. Today 1995, 16, 524-528
15. 7 mediates superoxide production in primary microglia and is upregulated in a transgenic mouse model of Alzheimer's disease J. Biol. Chem. 2003, 278, 13309-13317
16. 7 immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord BMC Neurol. 2006, 2, 6-12
17. 7 receptor in Alzheimer disease and amyloid-beta peptidetreated microglia and in peptide-injected rat hippocampus J. Neuropathol. Exp. Neurol. 2006, 65, 1090-1097
18. Philips, T.; Robberecht, W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease Lancet Neurol. 2011, 10, 253-263
19. 7- receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration FASEB J. 2009, 23, 1893-1906
20. 7 receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis J. Neurosci. 2007, 27, 9525-9533
21. 7 receptor is neuroprotective in an animal model of Alzheimer's disease NeuroReport 2008, 19, 1715-1719
22. 7 antagonist, oxidized ATP, in arthritic rats Neurosci. Lett. 2002, 327, 87-90
23. 7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain Pain 2005, 114, 386-396
24. 7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat J. Pharmacol. Exp. Ther. 2006, 319, 1376-1385
25. 7-related modulation of pathological nociception in rats Neuroscience 2007, 146, 1817-1828
26. 7 antagonist in animal models of pain and inflammation J. Pharmacol. Exp. Ther. 2008, 327, 620-633
27. 7-dependent release of interleukin-1β and nociception in the spinal cord following lipopolysaccharide J. Neurosci. 2010, 30, 573-582
28. 7 receptor pore formation regulates variability in chronic pain sensitivity Nat. Med. 2012, 18, 595-600
29. 7 receptor-pannexin connection to dye uptake and IL-1β release Purinergic Signalling 2009, 5, 129-137
30. Jarvis, M. F. The neuron-glial purinergic receptor ensemble in chronic pain states Trends Neurosci. 2010, 33, 48-57
31. 7 and the inflammasome Trends Pharmacol. Sci. 2007, 28, 465-472
32. 7 receptor. From lead identification to drug development J. Med. Chem. 2009, 52, 3123-3141
33. 7 antagonists J. Med. Chem. 2008, 51, 3030-3034
34. Liu, J.; Obando, D.; Liao, V.; Lifa, T.; Codd, R. The many faces of the adamantyl group in drug design Eur. J. Med. Chem. 2011, 46, 1949-1963
35. Battilocchio, C.; Baxendale, I. R.; Biava, M.; Kitching, M. O.; Ley, S. V. A flow-based synthesis of 2-aminoadamantane-2-carboxylic acid Org. Process Res. Dev. 2012, 16, 798-810
36. 7 receptors Mol. Pharmacol. 2000, 58, 82-88
37. 7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases Arch. Immunol. Ther. Exp. 2010, 58, 91-96
38. Iwamaru, Y.; Takenouchi, T.; Murayama, Y.; Okada, H.; Imamura, M.; Shimizu, Y.; Hashimoto, M.; Mohri, S.; Yokoyama, T.; Kitani, H. Anti-prion activity of brilliant blue G PLoS One 2012, 7 (5) e37896 10.1371/journal.pone. 0037896
39. 7 improves recovery after spinal cord injury Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 12489-12493
40. 7 receptor in astrocyte mediated motor neuron death: implications for amyotrophic lateral sclerosis J. Neuroinflammation 2010, 7, 33-42
41. 7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3 and secretases Neurobiol. Aging 2012, 33, 1816-1828
42. Jo, S.; Bean, B. P. Inhibition of neuronal voltage-gated sodium channels by brilliant blue G Mol. Pharmacol. 2011, 80, 247-257
43. Sadove, M. S.; Balagot, R. C.; Hatano, S.; Jobgen, E. A. Study of a Narcotic Antagonist: N -allyl-noroxymorphone JAMA, J. Am. Med. Assoc. 1963, 183, 666-668
44. Rinaldi-Carmona, M.; Barth, F.; Héaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Néliat, G.; Caput, D.; Ferrara, P.; Soubrié, P.; BrelieÌ€re, J. C.; Le Fur, G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett. 1994, 350, 240-244
45. Cervetto, C.; Maura, G.; Marcoli, M. Inhibition of presynaptic release-facilitatory kainate autoreceptors by extracellular cyclic GMP J. Pharmacol. Exp. Ther. 2010, 332, 210-219
46. 7 receptor activation Neurochem. Int. 2012, 60, 768-772
47. 7 receptors in adult rat cerebrocortical nerve terminals FEBS Lett. 2008, 582, 3948-3953
48. Ogita, K.; Hirata, K.; Bole, D. G.; Yoshida, S.; Tamura, Y.; Leckenby, A. M.; Ueda, T. Inhibition of vesicular glutamate storage and exocytotic release by Rose Bengal J. Neurochem. 2001, 77, 34-42